ARC-20 A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy and combination therapies in participants with clear cell renal cell carcinoma and other solid tumors

  • Phase I
  • Trial Category: Genitourinary, Other Solid Tumor

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Nebraska Cancer Specialists, Omaha, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*